after diagnosis. It was the beginning of an endless journey of asking more questions than there were answers available. As a medical intern and resident in Internal Medicine, it was deeply inspirational and uplifting to care for cancer patients in the hospital, who transmitted an aura of hope and optimism in the face of terminal illness. I had an inner reali- zation that the care of cancer patients provides a unique opportunity for humanism in medicine. During my clinical fellowship in Medical Oncology at Harvard, I lost a close maternal uncle to meta- static prostate cancer. At that time, I was emotion- ally humbled and intellectually challenged by the limited treatment options for patients with this disease, and so I dedicated my career to translating the most effective therapeutic approaches from the bench to the bedside to combat this disease. What is the most rewarding part of your job? The cancer problem is global, with an increasing need for international teams to come together to find creative solutions with a broader public health impact. It is an honor to be part of this international effort to end suffering from cancer. Who inspires you? I am continually inspired by our patients, who fight cancer with courage, optimism, and grace. I am grateful to my colleagues and team members, whose tireless efforts motivate me on a daily basis. I am deeply indebted to my family for their loving support, which serves as an inspiration for my efforts as a physician-scientist, even during the most challenging phases of this journey. What do you love about working at the University of Chicago? I particularly resonate with the culture of collegial- ity and team spirit at the institution. I am thankful for the invaluable commitment and support for translational research provided by the Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center. What is one thing on your bucket list? As a young boy growing up in India, I developed a love for science and a career in medicine/bio- medical research, which remains with me today. I hope to come back full circle and collaborate with institutions in India, to advance infrastructure for translational cancer research and clinical trials in areas with the greatest unmet need. Research Highlights Hormonal Therapy for Recurrent Prostate Cancer More than 30 percent of men who undergo surgery for prostate cancer will develop a recurrence, typically detected by a rise in the levels of the biomarker prostate specific antigen (PSA) in their blood. Radiation therapy is commonly used to treat these patients, as other anti-tumor strategies have not proven to be consistently beneficial. In a multicenter clinical trial involving biostatis- tician James Dignam, PhD, professor of public health sciences, researchers addressed whether drugs blocking androgen hormones (for exam- ple, testosterone) would improve cancer control and prolong survival. More than 750 prostate cancer patients were randomized to receive radiation and either daily doses of the antian- drogen bicalutamide or placebo for two years, and then followed for an average of 13 years. The research team found that overall survival was higher in those patients receiving bicalut- amide and radiation. Furthermore, the incidence of both metastatic prostate cancer and death from prostate cancer were significantly lower in this group compared to those patients treated with radiation and placebo. These findings are likely to change how physicians treat recurrent prostate cancer by combining antiandrogen and radiation therapy to improve outcomes. (Shipley et al., N Engl J Med 376:417-428, 2017) Research CANCER.UCHICAGO.EDU 7 Research